邀请牛人整理核苷类药物耐药/突变位点，有奖！

interdetect

为了方便交流，提高论坛战友知识储备，特有奖征集各核苷类药物的耐药/突变位点。发一条奖励10分！核苷类药物包括：拉米夫定、阿德福韦酯、恩替卡韦、替比夫定和替诺福韦。其他不奖励，但也不限制。
格式如下：
拉米夫定 ----  rtM204V





(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

lingmaigui

拉米夫定rtL180M

lingmaigui

恩替卡韦 rtM204V rtL180M rtS202G/I rtM250V rtT184G rtI169T rtV173L

lingmaigui

阿德福韦 rtA181V rtN236T

骗可乐30分够了

心路2009

楼上坏人，有齐全的资料就是不给可乐哥。

心路2009

乙型肝炎病毒耐药的标准化命名、检测及处理

乙肝病毒对核苷类抗病毒药物的耐药性－是难免的！   411老师的文章精品

放牛哥哥

我的签名档连接中有所有核苷的P区靶位记录。

lingmaigui

心路2009 发表于 2011-4-26 15:14
楼上坏人，有齐全的资料就是不给可乐哥。

小心心诽谤我，我根本没全套。
这玩意本来就是科研用的。我拿个全套资料来根本没啥用。

放牛哥哥

84#

bigben446

interdetect 发表于 2011-4-26 14:59
为了方便交流，提高论坛战友知识储备，特有奖征集各核苷类药物的耐药/突变位点。发一条奖励10分！核苷类药 ...

不少综述已经总结了

Title: Hepatitis B virus resistance to nucleos(t)ide analogues
Author: Zoulim, F.; Locarnini, S.
Source: Gastroenterology, 2009, 137(5): 1593-1608
Abstract:
  Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos(t)ide analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to treatment failure and progression to liver disease. There has been much research into the mechanisms of resistance to NA and selection of these mutants. Five NA have been approved by the US Food and Drug Administration for treatment of CHB; it is unlikely that any more NA will be developed in the near future, so it is important to better understand mechanisms of cross-resistance (when a mutation that mediates resistance to one NA also confers resistance to another) and design more effective therapeutic strategies for these 5 agents. The genes that encode the polymerase and envelope proteins of HBV overlap, so resistance mutations in polymerase usually affect the hepatitis B surface antigen; these alterations affect infectivity, vaccine efficacy, pathogenesis of liver disease, and transmission throughout the population. Associations between HBV genotype and resistance phenotype have allowed cross-resistance profiles to be determined for many commonly detected mutants, so genotyping assays can be used to adapt therapy. Patients that experience virologic breakthrough or partial response to their primary therapy can often be successfully treated with a second NA, if this drug is given at early stages of these events. However, best strategies for preventing NA resistance include first-line use of the most potent antivirals with a high barrier to resistance. It is important to continue basic research into HBV replication and pathogenic mechanisms to identify new therapeutic targets, develop novel antiviral agents, design combination therapies that prevent drug resistance, and decrease the incidence of complications of CHB.